AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
Recent Articles
RELATED ARTICLES
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US - InSilico seeks IPO boost to get AI drugs over the line
- ProfoundBio discovers the joys of having a wealthy owner
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
